Joint Research and Development of an Autologous Dendritic Cell Vaccine Pulsed with SARS-CoV-2 Antigen
First written in FY2022. 1 of 2 entries say "Dropped", first in FY2023-Q2. Latest entry: FY2023-Q2.
No other company in this theme has enough history to compare yet.
- FY2023-Q2DroppedAnnual report
「The SARS-CoV-2 antigen peptides used in the nonclinical trials have not produced sufficient results demonstrating their usefulness, and resolving these issues would require considerable time. After comprehensively considering the future development plans and other factors, we have decided to terminate this joint research and discontinue development of the autologous dendritic cell vaccine for the prevention of COVID-19.」
The joint research with the National Cancer Center Japan and Keio University on an autologous dendritic cell vaccine for the prevention of COVID-19 was terminated and development was discontinued. The data obtained are planned to be used in research and development for the prevention of other infectious diseases and cancer treatment. - FY2022First statedAnnual report
「As COVID-19 continued to spread, we considered whether our proprietary technology for zoledronic-acid-sensitized dendritic cells could be applied to COVID-19 vaccine development. In August 2020, we entered into a joint research and development agreement with the National Cancer Center to develop an autologous dendritic cell vaccine pulsed with SARS-CoV-2 antigen for the prevention of COVID-19, and are currently conducting preclinical studies.」
The Company first disclosed that it had signed a joint R&D agreement with the National Cancer Center in August 2020 and was conducting preclinical studies of an autologous dendritic cell vaccine pulsed with SARS-CoV-2 antigen.